|
🐜
|
Structural characterisation of a novel GPVI nanobody-complex reveals a biologically active domain-swapped GPVI dimer.
12 auth.
Alexandre Slater,
Ying Di,
Joanne C. Clark,
Natalie J. Jooss,
Eleyna M. Martin,
F. Alenazy,
...
Mark R Thomas,
R. Ariëns,
A. Herr,
Natalie S. Poulter,
J. Emsley,
S. Watson
|
4 |
2021 |
4
🐜
|
|
🦁
|
Novel antiplatelet targets in the treatment of acute coronary syndromes
F. Alenazy,
Mark R Thomas
|
4 |
2020 |
4
🦁
|
|
🐜
|
The Role of Vitamin D in Reducing the Risk of Metabolic Disturbances That Cause Cardiovascular Diseases
8 auth.
Z. Al-Oanzi,
F. Alenazy,
Hassan H. Alhassan,
Yasir Alruwaili,
Abdulaziz I. Alessa,
Nouf B. Alfarm,
...
Maha O. Alanazi,
Sarah I. Alghofaili
|
3 |
2023 |
3
🐜
|
|
🐜
|
Insight into Oncogenic Viral Pathways as Drivers of Viral Cancers: Implication for Effective Therapy
12 auth.
A. Elkhalifa,
S. U. Nabi,
O. Shah,
S. Bashir,
Umar Muzaffer,
Sofi Imtiyaz Ali,
...
I. Wani,
N. Alzerwi,
Abozer Y. Elderdery,
Awadh Alanazi,
F. Alenazy,
Abdulaziz Hamdan A. Alharbi
|
3 |
2023 |
3
🐜
|
|
🐜
|
Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs
7 auth.
M. Harbi,
Christopher W. Smith,
F. Alenazy,
P. L. R. Nicolson,
A. Tiwari,
S. Watson,
...
Mark R Thomas
|
3 |
2022 |
3
🐜
|
|
🦁
|
GPVI inhibition by glenzocimab synergistically inhibits atherosclerotic plaque-induced platelet activation when combined with conventional dual antiplatelet therapy
15 auth.
F. Alenazy,
M. Harbi,
D. Kavanagh,
Joshua Price,
P. Brady,
O. Hargreaves,
P. Harrison,
Alexandre Slater,
D. Connolly,
P. Kirchhof,
...
N. Kalia,
M. Jandrot-Perrus,
P. Mangin,
S. Watson,
Mark R Thomas
|
2 |
2021 |
2
🦁
|
